目的：探讨G蛋白偶联受体5（LGR5）分子在宫颈癌患者病理组织的表达规律及其意义。方法选择由31例Ⅲb期宫颈癌患者癌瘤和癌旁组织构建的组织芯片，以兔抗人LGR5抗体为第1抗体和辣根过氧化物酶标记的抗兔抗体为第2抗体进行免疫组织化学染色，并采用Aperio病理扫描系统结合2名病理科医师进行读片和结果分析；而后，采用免疫荧光染色和流式细胞术检测LGR5分子在宫颈癌细胞株HeLa细胞膜的表达；进而采用0、0.2、1、5 ng/mL等不同浓度的人R-脊椎蛋白1（RSPO1）刺激HeLa细胞，采用细胞计数法观察HeLa细胞的增殖情况。结果宫颈癌组织鳞状上皮LGR5染色强度31例均为Ⅰ级，癌旁鳞状上皮组织LGR5染色27例为Ⅰ级，4例为0级。LGR5分子在宫颈癌组织的表达率为（70.00±4.57）%，明显高于其在癌旁组织的表达率（23.39±4.20）%（P＜0.01）。宫颈癌细胞株HeLa细胞膜表达LGR5分子，RSPO1可在体外促进HeLa细胞增殖。结论干细胞标记分子LGR5表达于宫颈癌组织，并参与宫颈癌细胞的增殖。LGR5是宫颈癌临床靶向干预的可能靶点。%ObjectiveTo explore the expression pattern and the biological role of LGR5 on cervical cancer. Methods Tissue chips that contain the tumor tissue and tumor adjacent tissue from 31 cervical cancer patients were stained with rabbit anti-human LGR5 antibody and HRP labeled anti-rabbit antibody. And then the tissue chips were analyzed with Aperio pathological scan system and 2 experienced pathologists. LGR5 expression on HeLa cell was detected with immunofluorescence staining and flow cytometry. Different concentration of RSPO1 (0, 0.2, 1 and 5 ng/mL) to stimulated HeLa cell in vitro and cell counting was performed to evaluated its proliferation.Result LGR5 expressed on the tumor tissues from all the patients (31/31) and tumor adjacent tissues from 27 patients (27/31), the staining scale isⅠ. But the LGR5 expression ratio (70.00%±4.57%) of tumor tissue is higher than its expression ratio (23.39%±4.20%) of tumor adjacent (P﹤0.01). Cervical cancer cell line HeLa expressed membrane LGR5 and its proliferation could be accelerated by RSPO1 stimulation in vitro.Conclusion Stem cell marker LGR5 was expressed on cervical tumor tissue and it plays the important role on cervical cancer cell proliferation. LGR5 is the promising target of cervical cancer therapy.
展开▼
